Melanoma Matters

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE...

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of interest include...

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on gene expression...

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG. Megan talks about growing up in the PNW and going East to get back West. She...

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications. They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on...

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting. OptimUM-02 ADAM KN-942 Neoadjuvant pilot studies ... and more

Summary The conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial...

Summary Happy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music, books, plays...

Summary In this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-year outcomes of...

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

Summary So many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and...

Summary In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Merrick Ross, a seasoned surgical oncologist, discussing his background, the evolution of surgical practice with regards to...

Summary In this Episode, hosts James & Sapna go into the 7-year follow-up from the randomized phase 3 adjuvant trial of pembrolizumab versus placebo for stage III melanoma, KEYNOTE-054 There's a bit too much talk about...

Summary In this (longest to-date) episode, James and Sapna delve into the not-so-rare occurence of immune-mediated myocarditis, particularly in the context of immune checkpoint inhibitors. The hosts discuss grading...

Summary In this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial...